ESR1 and breast carcinoma: To investigate SEMA3C’s potential role as a driver of breast cancer, we needed to induce SEMA3C signaling via the stimulation of ER+ breast cancer cells and examine whether SEMA3C can activate RTK signaling pathways that are commonly observed in breast cancer.